ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PACS
UHS (62) ENSG (68) EHC (77) NHC (72) ⌘ Pro Terminal →

PACS Group Inc. (PACS) — RQD Stock Rating Cockpit

$45.58 -4.66% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $45.31

PACS Group Inc. (PACS) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (steady margins, 25% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $7.57B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PACS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PACS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, PACS Group Inc. (NYSE: PACS) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $45.58 (-4.66% 1D, market cap $7.57B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, PACS ranks #48 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PACS compare to UHS and ENSG in the Health Care sector?
▼

Within the Health Care sector (Hospital/Nursing Management), PACS carries a Roarable B (73/100 RQD), trailing P/E of 41.1x, gross margin of —, and ROIC of 24.6%. By comparison, UHS (Universal Health Services Inc.) holds a C grade (62/100 RQD, P/E 7.0x, ROIC 14.1%, cap $10.38B) and ENSG (The Ensign Group Inc.) posts a C+ grade (68/100 RQD, P/E 31.6x, ROIC 18.0%, cap $10.59B). Among the 5-stock peer group, UHS leads on earnings multiple (7.0x) while PACS leads on capital efficiency (24.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PACS?
▼

Per PACS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002001184), PACS Group Inc. generated $5.29B in revenue (+29.4% YoY), $191.5M in net income, and $166.3M in free cash flow against $5.58B in total assets and $244.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 41x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $45.31 (-0.60%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 3.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510073
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B · Rk B
Cash (13)Whales (16)SEC (14)Macro (15)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+6.8% Base Target
$57 Bull$49 Base$37 Bear
📬 FREE PACS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PACS)Realized 20D OHLCV Swing Band: ±7.8%
Deterministic 5-Pillar Attribution (73/100 Composite)
🔍 WHY PACS SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (22% of score)

20D Institutional Volume Accumulation (±7.8% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+15/20 pts (21% of score)

FRED Regime × Technicals: 88% of 52W Range • RSI-14 at 54.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality13/20 pts (-7 pt drag)

Capital intensity & 5.9% operating margin leave 7 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
65
Grade C+$44.98+4% Next Q
Q2 (-2Q)
68
Grade B-$46.76+4.9% Next Q
Q3 (-1Q)
70
Grade B$49.06-7.1% Next Q
Current
73
Grade B$45.58+7.1% Hist 90D α
Trajectory: C+ (65) → B (73)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PACS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 73/100 (B) score, PACS faces multiple-compression risk if 41.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 41x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($44.48) or 200D SMA ($39.88) invalidates the momentum regime and cuts Target Base ($48.66) toward Bear Floor ($37.38).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PACS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PACS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 73%NO 27%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
54.830 Oversold · 70 Hot
ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)
2.24>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE88% OF RANGE
L: $10$45.58H: $50
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: B+RQD 31 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 29 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bullish on PACS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (65)

24.6% ROIC with 42.0% gross margin and 2.11% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 2.24 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (77)

31/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like PACS
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
  • ✓Company leadership has skin in the game with net positive insider conviction.
Bear Case: What Could Go Wrong
  • !Priced at 41x earnings—high expectations leave less room for a lukewarm quarter.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (PACS Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PACS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +40.16%▲ ASCENDING CHANNEL
2026-11-03O $49.68H $49.68L $45.58C $45.58VOL 591.3K
RES: $50.46SUP: $41.40SMA50: $44.48SMA200: $39.88
$52.15$44.83$37.51$30.19$22.87RES $50.46SUP $41.40$45.582026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PACS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PACS Butterfly Map → + Track PACS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
31.1%/yr Implied 5Y Growth

vs. +29.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PACS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PACS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PACS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PACS)

Health Care Rank #48 of 1015 ⚔️ UHS vs PACS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PACS vs. UHS, ENSG, EHC, NHC)

Industry: Hospital/Nursing Management (14 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, PACS Group Inc. (PACS) ranks #48 by composite RQD confidence (73/100, grade B) and #127 by equity capitalization ($7.57B). Within this direct 5-issuer industry benchmark cohort, UHS leads on earnings valuation at 7.0x trailing P/E, while PACS leads on capital efficiency and profitability with 24.6% ROIC and — gross margin. EHC currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with PACS at 73/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PACS ACTIVE
PACS Group Inc.
B 73/100 41.1x — 24.6% -4.66% $7.57B Benchmark Subject
UHS
Universal Health Services Inc.
C 62/100 7.0x — 14.1% +2.61% $10.38B /uhs-vs-pacs →
ENSG
The Ensign Group Inc.
C+ 68/100 31.6x 20.1% 18.0% -1.35% $10.59B /ensg-vs-pacs →
EHC
Encompass Health Corporation
B+ 77/100 22.9x — 13.8% +0.95% $13.41B /ehc-vs-pacs →
NHC
National HealthCare Corporation
B 72/100 27.7x — 10.1% -1.96% $3.23B /nhc-vs-pacs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002001184 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PACS Group Inc. (PACS) reported GAAP revenue of $5.29B (+29.4% vs. FY2024 revenue of $4.09B , and +70.0% cumulative change since FY2023) , GAAP net income of $191.5M, operating cash flow of $404.2M, and free cash flow of $166.3M (-9.4% YoY). On the balance sheet, PACS closed FY2025 with $5.58B in total assets against $244.8M in total debt (Altman Z-Score: 2.24, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $5.29B $191.5M $404.2M $166.3M $5.58B $244.8M
FY2024 (FY) 2024-12-31 $4.09B $55.8M $367.3M $183.4M $5.24B $251.0M
FY2023 (FY) 2023-12-31 $3.11B $112.9M $63.7M -$76.3M $4.33B $1.01B

3. PACS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PACS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, PACS Group Inc. (NYSE: PACS) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $45.58 (-4.66% 1D, market cap $7.57B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, PACS ranks #48 in composite RQD confidence.

How does PACS compare to UHS and ENSG in the Health Care sector?

Within the Health Care sector (Hospital/Nursing Management), PACS carries a Roarable B (73/100 RQD), trailing P/E of 41.1x, gross margin of —, and ROIC of 24.6%. By comparison, UHS (Universal Health Services Inc.) holds a C grade (62/100 RQD, P/E 7.0x, ROIC 14.1%, cap $10.38B) and ENSG (The Ensign Group Inc.) posts a C+ grade (68/100 RQD, P/E 31.6x, ROIC 18.0%, cap $10.59B). Among the 5-stock peer group, UHS leads on earnings multiple (7.0x) while PACS leads on capital efficiency (24.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PACS?

Per PACS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002001184), PACS Group Inc. generated $5.29B in revenue (+29.4% YoY), $191.5M in net income, and $166.3M in free cash flow against $5.58B in total assets and $244.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 41x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PACS trading relative to its 50-day, 200-day, and 52-week technical levels?

PACS last traded at $45.58 (-4.66% on volume of 875,050 shares), positioning the stock +2.47% above its 50-day simple moving average ($44.48) and +14.29% above its 200-day simple moving average ($39.88). Across its 52-week range of $10.31 to $50.38, PACS sits at the 88.0% percentile with a 14-day RSI of 54.8 (NEUTRAL RANGE) and an implied next-earnings move of ±7.8% ($42.02 to $49.14).

Direct Sub-Reports: PACS RQD Cockpit PACS 12M Forecast PACS Earnings & Move PACS Dividends & DRIP PACS Insiders & 13F PACS Whale Options PACS Profit Sankey PACS News & Why
ROARABLE RATING BRIEF • RQD 73/100 (B) ✓ SEC XBRL & RQD VERIFIED

PACS — PACS Group Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

PACS Group Inc. (PACS) earns a live Roarable RQD composite score of 73/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $45.58 (-4.66% 1D, market capitalization $7.57B).

  • Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 24.6%, gross margin of —, operating margin of 5.9%, and free cash flow yield of 2.11%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (15/20) + Forensic Balance Sheet (14/20): Incorporates a 0.95x equity beta, Altman Z-Score of 2.24, Piotroski F-Score of 9/9, and Debt/Equity of 0.26x.

2. Business Model, Unit Margins & SEC Financial Trajectory

PACS Group Inc. Is a NYSE-listed issuer in the Health Care sector, operating in the Hospital/Nursing Management industry. The profile identifies it as a long-term care operator. FY 2025 revenue was $5.29B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), PACS Group Inc. (PACS) reported $5.29B in annual revenue (up from $4.09B in FY2024, +29.4% YoY) and $191.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.11B revenue, $112.9M net income) through FY2025, PACS scaled operating cash flow to $404.2M and free cash flow to $166.3M, backed by $5.58B in total assets against $244.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B • RQD 73/100): Big institutional funds and options desks are actively positioning on the bullish side. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $10.31 – $50.38 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Priced at 41x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 41.1x trailing P/E and 15.5x EV/EBITDA against 5.9% operating margins and a 0.95x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream supply-chain links are recorded and no proprietary signals are present. Upstream dependencies, downstream customers, sector correlations, and 2nd-order bottlenecks are — An investor should note that the absence of mapped links means this brief cannot assess ripple effects from suppliers, payers, or adjacent healthcare operators.

  • Key Question #1: Can PACS sustain or expand its 5.9% operating margin and 24.6% ROIC against Hospital/Nursing Management peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $5.29B and free cash flow of $166.3M, how will capital allocation balance growth reinvestment against $244.8M in total debt?
  • Key Question #3: How sensitive is PACS's 34.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.95x)?

PACS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PACS Group Inc. (PACS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PACS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PACS Bull vs. Bear Conversation Board — What's Your Call at $45.58?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PACS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PACS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $58.81 (+23.0%)
📌 Pinned Debate

Per the Roarable RQD rating, institutional accumulation (17/20) is the strongest pillar, with ROIC of 24.6% and Piotroski F-Score of 9/

The street is overcomplicating PACS Group Inc. (PACS). Per the Roarable RQD rating, institutional accumulation (17/20) is the strongest pillar, with ROIC of 24.6% and Piotroski F-Score of 9/9 supporting the business quality case.. With an RQD score of 73/100 (B) and Forensic Balance Sheet at 14/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $51.63.

VolSurface_Trader 🐂 BULL

Both sides have a point here — PACS's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $39.20 (-18.0%)
Spot @ $47.81

Per the market data section, trailing P/E of 41.1 and FCF yield of 2.11% leave little valuation cushion if earnings growth slows.

Sitting on the sidelines or leaning short PACS above $47.81. Per the market data section, trailing P/E of 41.1 and FCF yield of 2.11% leave little valuation cushion if earnings growth slows.. Until Fundamental Cash Engine (13/20) and FCF yield (2.11%) inflect higher, upside is capped near $50.38.

LIVE TAPE